anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel method of treating localized solid tumors and papillomas in an individual as well as metastatic carcinoma.  &lt;P&gt;SOLUTION: The therapy comprises delivering a suicide gene, by way of a recombinant adenoviral vector or other DNA transport system, into the tumor, papilloma or wart of an individual. Subsequently, a prodrug, such as the drug gaciclovir(R), is administered to the individuals. Additionally, the therapy provides a method for treating solid tumors, papillomas, warts and metastatic carcinomas, the method comprising introducing both a suicide gene and one or more cytokine gene into the tumor, papilloma or wart of an individual, and subsequently administering a prodrug to the individual. The methods may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain lymphoma and head and neck cancer.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe and useful therapeutic agent for chronic obstructive pulmonary diseases.  &lt;P&gt;SOLUTION: The present invention relates to a compound represented by the general formula (I) (wherein all symbols represent specific means), its salt, its solvate or its cyclodextrin clathrate compound or a prodrug thereof. The prodrug thereof has strong bronchodilator activity. Furthermore, the compound represented by general formula (I) has anti-inflammatory activity. Consequently, the compound represented by general formula (I) is effective in the treatment of respiratory diseases such as chronic obstructive pulmonary disease, adult respiratory distress syndrome, emphysema, cystic fibrosis, and chronic bronchitis.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:A binder, containing gelan gum as a principal material, advantageous for industrial production as a binder for cataplasm, ointment, suppository, etc., and having high binding effect. CONSTITUTION:A binder for formulating medicines containing gelan gum as a principal material. Gelatin, colloid similar thereto or aqueous gel thereof has been normally used as a binder used in cataplasm, ointment, suppository, etc., but there are disadvantages, e.g. gelatin, etc., outflows in cataplasm, etc., at a high temperature in the summer season to reduce the drug efficacy for a part to be applied since the flow starting point of the gelatin is as low as about 250 deg.C. Since the sol formation temperature of the principal material gelan gun is &gt;=70 deg.C, the heat stability is much better than that of the gelatin and thermal decomposition is hardly caused. The resultant pharmaceutical using the above-mentioned binder has very high heat stability and acid and alkali resistance and further is readily used without toxicity to human bodies.
PROBLEM TO BE SOLVED: To obtain a new lipase inhibitor by using a specific triterpene compound and its derivative as active ingredients and further to obtain cosmetics, pet foods and foods which are excellent in lipase inhibitory activity and high in safety by formulating this inhibitor thereto. SOLUTION: These cosmetic, pet food and food contain at least one kind selected from the group consisting of a compound of formula I or II [R&lt;1&gt; is OH and O-C(O)-CH3 ; R&lt;2&gt; to R&lt;4&gt; are each H, CH3 , CH2 OH, etc.; R&lt;5&gt; to R&lt;8&gt; are each H and CH3 ; R&lt;9&gt; is OH and the like; R&lt;10&gt; to R&lt;12&gt; are each H, CH3 , etc.] and its derivative as active ingredients. As the lipase inhibitor, the compound of formula II and its derivative are particularly preferable. By formulating this lipase inhibitor with cosmetic materials, pet foods and foods, skin eruptions, pimples and skin roughening can be continuously suppressed and further the inhibitor can be utilized for preventing foods containing oils and fats from deterioration. Furthermore, the calorie of foods and feeds can be decreased and in addition adult diseases are effectively prevented.
The services provided according to the subject invention address the important medical, financial, legal and/or lifestyle issues affecting the global health and well-being of adult women worldwide. Specifically, the overall well-being of adult women is improved by providing services and information which help women prevent and/or treat medical conditions, as well as address other factors which directly affect the well-being of the adult woman. The subject invention provides a comprehensive system whereby adult women are provided with information and/or services relating to 1) medical issues and 2) quality of life care issues. In a preferred embodiment, the subject invention provides an organizational structure to facilitate providing a multiplicity of services beneficial to adult women. This organizational structure is dedicated to adult women, typically aged 16 and over, helping them to achieve optimum health and quality of life through an integrated program which provides adult women&#39;s medicine, legal, financial, and lifestyle information and services. These services can be made available to the professional and consumer public via a single web-site in sponsored neighborhood home gatherings, televised Town Hall meetings, and various print materials including but not limited to a journal.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sport drink and a sport food promoting fatigue relief through increasing addition of citric acid as much as possible within an acceptable limit as a beverage so as to reduce a lactic acid value due to effect of the citric acid.  &lt;P&gt;SOLUTION: The sport drink is obtained by adding ≥1.2 pts. wt. of the citric acid to 100 pts. wt. (ml) of drinking water; adding an appropriate amount of glucose, fructose, fruit juice, a gelling agent, a pH adjusting agent, and the like, to the mixture; and diluting the mixture with drinking water so as to have an appropriate concentration.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention relates to the technical field of preservatives. The invention provides a composition containing p-hydroxyacetophenone, a preparation method and an application thereof, wherein the composition comprises the following components in parts by weight: 10-40 parts of p-hydroxyacetophenone, 30-70 parts of C3-C8 dihydric alcohol and 1-6 parts of plant extract. The preservative prepared by the composition is safe and efficient, has a wide antibacterial spectrum and good water solubility, and is convenient to use. Not only can be independently used as a preservative system in a cosmetic formula, but also can be used together with the traditional preservative, so that the dosage of the traditional preservative is reduced. Can also be used as a conceptual &#39;no-additive&#39; raw material and is independently applied to products, and the anti-corrosion effect is good. Meanwhile, harmful substances such as formaldehyde and the like cannot be released in various cosmetics, and the skin care product is mild and does not irritate the skin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new peritoneal deterioration inhibitor, a peritoneal dialytic fluid and a method for peritoneal dialysis, inhibiting peritoneal deterioration using a rare saccharide.  &lt;P&gt;SOLUTION: The peritoneal deterioration inhibitor characterized by containing a rare saccharide is provided, wherein the rare saccharide is selected from the group consisting of d-psicose, L-psicose, D-allose, L-sorbose, D-fructose, L-tagatose, D-sorbose, L-fructose and D-tagatose. This peritoneal deterioration inhibitor is characterized by containing, in addition, glucose. This inhibitor is to be used by compounding in a peritoneal dialytic fluid. The peritoneal dialytic fluid is characterized by containing the above inhibitor. This peritoneal dialytic fluid is characterized by containing, in addition, glucose and an electrolyte. The method for peritoneal dialysis is characterized by involving using a dialytic fluid containing an effective amount of the above rare saccharide or its salt.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a medicine composition which treats JC virus infected diseases, e.g., progressive multifocal leukoencephalopathy (PML) by inhibiting expression of agnoprotein and suppressing proliferation of JC virus, a polynucleotide therefor and a use thereof.  &lt;P&gt;SOLUTION: The medicine composition for treating JC virus infected cells by an RNAi (RNA interference) method comprises using a short interfering RNA (siRNA) against a gene encoding JC virus agnoprotein. The polynucleotide is an active ingredient therefor. The medicine composition for treating JC virus infected diseases comprises a short interfering RNA (siRNA) against a gene encoding JC virus agnoprotein or a gene forming the siRNA and a pharmaceutically permissible carrier. The polynucleotide therefor is obtained. The gene is used for producing the medicine composition.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject medicine having high wound healing effect by embedding leukocyte or bone marrow cell into a matrix or attaching leukocyte or bone marrow cell to the matrix. SOLUTION: This agent is obtained by separating leukocyte or bone marrow cell from blood, mixing the separated leukocyte or bone marrow cell with a matrix (preferably biodegradable collagen, chitin, fibrin, etc.) in solution state, gelatinizing the mixture, as necessary, culturing the resultant gel in a solution containing cytokine (e.g. γ-interferon), a cell growth factor or a stimulating agent (e.g. a cyclic peptide of the formula and obtained by culturing Streptomyces nobilis, preferably in an amount of 10&lt;-16&gt; to 10&lt;-2&gt; based on culture medium). The agent has activated leukocyte or bone marrow cell. Strong wound healing promoting effect is exhibited by bringing the agent into contact with the wound part.
NEW MATERIAL:A 5-fluorouracil derivative expressed by formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is 1-20C straight-chain or branched chain alkyl; X is O or single bond) and pharmacologically acceptable salt thereof. EXAMPLE:4-O-Pivaloyloxymethyl-5-fluorouracil. USE:An antitumor agent. PREPARATION:A compound expressed by formula II (M is Na, K, Ag, Hg, etc.; R&lt;3&gt; is a protecting group of hydroxyl group, such as halogeno-lower alkyl or alkyl substituted by 1-3 aryl groups) is reacted with a compound expressed by formula III (Z is halogen, alkylcarbonyloxy, etc.) to provide a compound expressed by formula IV. The protecting group of the hydroxyl group is then eliminated to afford the aimed compound expressed by formula I.
The invention comprises substituted imidazolones of the general formula &lt;FORM:0757650/IV(a)/1&gt; wherein n is 2 or 3, and their acid addition and quaternary salts, and the preparation thereof by condensing a carboxylic acid of the general formula &lt;FORM:0757650/IV(a)/2&gt; wherein n has the above significance or a lower alkyl ester or nitrile thereof, with ethylenediamine or an acid addition salt thereof.  Suitable esters are the methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl esters.  The reaction is preferably carried out by heating, e.g. the nitrile may be heated with the p-toluenesulphonic acid salt of ethylene diamine.  The acid addition salts are prepared by contacting the free imidazolines with an acid to form, for example, the tartrate, citrate, phthalate, lactate, formate, phosphate, nitrate, sulphate, hydrochloride, hydrobromide, hydroiodide and acetate salts, and the quaternary salts are formed by reaction with an ester, e.g. an alkyl halide or sulphate such as dimethylsulphate, methyl iodide, ethyl bromide and propyl chloride.  In the examples, 2-(1,2,3,4-tetrahydro - 1 - naphthyl) - imidazoline and its hydrochloride, dehydrogen phosphate, hydrobromide, cyclohexylsulphamate, bitartrate and saccharinate salts and the hydrochloride salt of 2-(1-indanyl)-imidazoline are prepared. Intermediate compounds.  1,2,3,4-Tetrahydro-1-naphthonitrile is prepared by heating the corresponding 1-naphthoamide with thionyl chloride.  Lower alkyl esters of 1,2,3,4-tetrahydro-1-naphthoic acid and 1-indone-carboxylic acid are prepared by heating the free acids with alcohols, e.g. methyl alcohol.
PROBLEM TO BE SOLVED: To obtain a powdery cosmetic having light use feeling, strong coloring power with slight variation of coated color with passing of the time by including colored powder and an oil agent. SOLUTION: This powdery cosmetic is obtained by including (A) 1.5-40 wt.% of colored powder selected from iron oxide and tar-based pigment and (B) 1.5-30 wt.% of an oil agent liquid at a normal temperature. Preferably, a weight ratio of the component B to the component A, (B/A) is 0.05-5. Preferably, the cosmetic is a foundation. Preferably, a particle diameter of the component A is 0.005-μm. The component A having hydrophobic-treated surface obtained by using a hydrophobizing treating agent such as an silicone oil can be used. Preferably, the component B is an oil and fat or a silicone oils having &lt;=500 mm2/s viscosity at 20 deg.C. Preferably 1-60 wt.% of globular powder having an average particle diameter of 1-50 μm (e.g. globular silica) and/or elastic powder (e.g. crosslinked-type silicone) can be mixed in the whole composition of the cosmetic.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a human amnion-derived mesenchymal cell having a high hypoglycemic effect and a new diabetic medicine useful for treating diabetes.  &lt;P&gt;SOLUTION: The human amnion-derived mesenchymal cell is immortalized by transferring an exogenous immortalized gene (e.g. TERT gene or E6 gene and E7 gene of human papillomavirus) to the cell. The immortalized human amnion-derived mesenchymal cell develops a remarkable hypoglycemic action. The immortalized human amnion-derived mesenchymal cell is used as an active ingredient for a diabetic medicine.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention relates to the use of IL-15 or active variants thereof and/or IL-15 activity enhancing compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system, such as manipulating viability ad/or responsiveness of said memory cells. The IL-15 activity enhancing compound is for example lipopolysaccharidc (LPS). The invention further relates to the use of IL-15 inhibiting or eliminating compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system. Such inhibiting or eliminating compounds are for example anti-IL-15 antibodies, anti-IL-15Ralpha antibodies, fragments of these antibodies, e.g. the Fab or F(ab&#39;)2 fragment, soluble IL-15Ralpha, fusion proteins consisting of soluble IL-15Ralpha, and Fc fragment, compounds, e.g. peptides, binding and/or inhibiting functional IL-15 receptor, IL-15 antisense oligonucleotides.
PROBLEM TO BE SOLVED: To have steady abundance of salicylic acid glycol in a sacciform body even in long-term preservation by enclosing a sacciform body and a plaster in wrapping whose top internal layer is made of one or more than two kinds of polyolefin, polyacrylonitrile and denatured PET. SOLUTION: A plaster is made of a sacciform body and a support. Combining water and salicylic acid glycol, which is widely used as embrocation, makes the sacciform and the support&#39;s contacting part with the sacciform is made of polypropylene. The plaster is enclosed in wrapping whose top internal layer is made of one or more than two kinds of polyolefin, polyacrylonitrile and denatured PET. In this case, an ideal combination quantity of salicylic acid glycol is 0.5% to 2% of the sacciform body&#39;s weight, and an ideal quantity of water is 40% to 85% of the sacciform body&#39;s weight. Ideal wrapping&#39;s top internal layer is Polyethylene and it has thickness of 20 μm to 40 μm. One provided with aluminum evaporated film layer is deal as a wrapping material.
Provided are systems, methods, and apparatuses for a portable hydration system including a mechanical or electromechanical mechanism for dispensing additives into a liquid or other solute in a portable container. Such additives include solids, liquid, powders, and gases, and include vitamins, minerals, nutritional supplements, pharmaceuticals, and other consumables. Additives are introduced into the hydration device via closed vessels equipped with RFID tags or similar, capable of transferring data about the vessels&#39; contents to the device. Dispensing is initiated manually by direct user action, automatically by the device, and/or externally through an associated application on a user device. Dispensing is adjustable by contextual factors such as a user&#39;s preferences, location, activity, physiologic status, and the like, obtained via APIs to third party applications or through more direct measurements or inputs. Consumption of additives and consumable liquids in the container is measured and monitored, and the data used to generate recommendations.
Adeno-associated virus (AAV) gene therapy vectors express a therapeutic protein or RNA that treats a genetic defect in a cell. The present disclosure provides AAV gene therapy vectors that additionally express an anti-inflammatory protein or peptide. When the provided AAV gene therapy vectors are used in methods of treatment of, for example, neurodegenerative diseases, the therapeutic protein/RNA treats the genetic defect within the cells directly transduced by the AAV vectors while the anti-inflammatory protein/peptide is secreted by the transduced cells into the intercellular milieu and treats microglial activation associated with the neuroinflammatory component of the neurodegenerative diseases. The therapeutic protein and anti-inflammatory protein/peptide can be expressed as fusion protein in which the two are separated in the fusion protein by a self-cleaving peptide. The anti-inflammatory protein/peptide can alternatively be expressed from a separate vector from the AAV gene therapy vector. The provided AAV gene therapy vectors and methods are thus useful in treating neurological and neurodegenerative disorders such as Amyotrophic Lateral Sclerosis, Duchenne&#39;s Muscular Dystrophy), spinal muscular atrophy, Batten diseases (CLN1/3/6/8), an IGHMBP2-related disorder, and PGAP3 Congenital Disorder of Glycosylation, including the neuroinflammation associated with the disorders.
553,465. Vitamins ; butyl alcohol and acetone. COMMERCIAL SOLVENTS CORPORATION. Nov. 13, 1940, No. 16445. Convention date, Oct. 24. [Class 2 (iii)] [Also in Group VI] In the fermentation of carbohydrate mashes to produce riboflavin together with butyl alcohol and acetone, particularly by means of Clostridium acetobutylicum (Weizmann), the operation is effected with precautions to reduce or exclude the presence of iron, nickel, cobalt, copper, lead and zinc. The amount of these metals or their compounds permitted should be not more and preferably much less than one tenth of the amount which would substantially reduce the yield of solvents. To effect this the grain used may be cleaned by blowing, or the grain or meal subjected to magnetic separation and materials containing these metals, such as molasses, avoided. Condensed steam which has passed through iron pipes and the use of iron vessels in contact with the wash should be avoided, but the precautions are less necessary after the &#34; acid break.&#34; The apparatus may be of aluminium or its alloys, and it is stated that small quantities of aluminium in the mash may improve the yield of riboflavin. Examples describe the effects of various small quantities of the specified metals on the yields of riboflavin and solvents. Specification 527,478 is referred to.
FIELD: medicine, immunology. SUBSTANCE: invention relates to drugs showing immunomodulating effect. Preparation consists of a mixture of human serum albumin and interleukin-1-beta taken at mass ratio (20-60):1. Preparation can contain additionally lactose at the dose 1-3 mg/1 mcg. Preparation &#34;Betaleukin&#34; shows capability to stimulate leukopoiesis under conditions of its profound depression at toxic leukopenia among them at &#34;febrile neutropenia&#34; caused by using some cytostatics or their combinations in therapy of malignant tumors. Preparation shows an effective curative effect at leukopenia caused by effect of ionizing radiation and radioprotective properties also. Preparation shows the pronounced immunostimulating effect and can be used for treatment of patients with secondary immunodeficient states caused by surgery operations and traumas. Highly active immunomodulating preparation &#34;Betaleukin&#34; does not contain allergic impurities and inert proteins, arectogenic and shows good tolerance in its final form. EFFECT: enhanced effectiveness of a preparation. 2 cl, 5 tbl, 7 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new process for preparing himbacine analogs useful as thrombin receptor antagonists.  &lt;P&gt;SOLUTION: There is provided the new process for preparing compound 11 from compound 1 (each described in the specification). The process provides an improved yield and the elimination of the need for chiral intermediates. The process is partially based on the use of base-promoted type dynamic epimerization of a chiral nitro center. In another embodiment, there are provided the compounds prepared by the process.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Enterically administrable diagnostic compositions for investigating alimentary functions comprising multiple units of a size of at the most 5 mm, preferably between 0.5 and 1.3 mm, in particular between 0.7 and 1.0 mm, each unit comprising a tracer substance binding agent (such as an ion exchange resin) with which a radioactive tracer substance with a half-life of at the most 5 days, in particular  99m  Tc,  113m  ln,  111  ln and  129  Cs, is associated. The tracer substance binding agent is being formulated with pharmaceutically acceptable excipients, in particular granulating excipients, in such a way that the exposure of the gastrointestinal mucosa to the tracer substance binding agent is reduced and that the units do not disintegrate during the passage through the gastrointestinal tract. Preferred units comprise cross-sectionally substantially homogeneous multi-component cores in which the tracer substance binding agent is granulated with one or more excipients and which are optionally coated. 
     Preferred units comprise cross-sectionally substantially homogeneous multi-component cores made by granulating the tracer-binding agent surface properties. Tracer substances are normally present in an amount from about 2 to about 20% by weight, preferably from about 5 to about 10% by weight, calculated on the units. Due to low leaching and the non-disintegrating properties, the composition can be used to investigate gastric emptying also of the last 20% of a food bolus, cf. FIG. 2 which illustrates the average gastric emptying pattern for 7 healthy volunteers (A) compared to the emptying from a person with the &#34;Giesskannen&#34; phenomenon (B).